Depression can be an almost intolerable burden to live with. While antidepressants help many to soothe their symptoms, many others find no relief in these substances. A decades-old drug, ketamine, is now offering hope to many of these people. Ketamine was first discovered in 1962.
"We're particularly interested in training students to enter the growth pharmaceutical industry surrounding the use of these substances, providing them with the tools to understand the data and also to work in an ethical manner and adhere to all the regulatory pieces surrounding the use of these compounds," he said.
A couple of companies in the Magic Mushroom sector that are worth talking about are Compass Pathways (CMPS) and Minerco, Inc. (MINE). CMPS is ahead in the race is already working on a formulation of psilocybin to help with treatment-resistant depression.
With the popularization of 5-MeO-DMT as a powerful substance for self-exploration and reconnection with the essence of life, side effects such as the now-famous reactivations (flashbacks) have also been revealed.
Tribes across the Amazon basin have been drinking Ayahuasca for a thousand years with the goal of spiritual healing, connecting with the divine, and cultivating telepathy. Shamans are said to be able to drink the brew and locate an animal of prey in the spirit world, then instruct hunters to its location in the physical world.
For our Saturday edition of The Daily Dive, host Cassandra [...]
Canada-based Algernon announced its clinical program in January based in part on a preclinical study published last year in Experimental Neurology by researchers from Semmelweis University, which showed DMT can promote neurogenesis and neuroplasticity in a rat model of brain ischemia.
The most common supervisor was a friend or partner, followed by a shamen (a spiritual practitioner), a therapist or counsellor and a family member. The most commonly used substances taken under supervision were LSD, magic mushrooms and ayahuasca.
Earlier this week, NeonMind (NMDBF) filed for four provisional patents. Psilocybin Alpha said, "The provisional patent applications include data derived from NeonMind's initial preclinical trial that began in November 2020, which examined the potential use of psilocybin as a treatment for weight loss.
Microdosing is the act of consuming sub-perceptual (unnoticeable) amounts of a psychedelic substance. Many individuals who have integrated microdosing LSD into their weekly routine report higher levels of creativity, more energy, increased focus, and improved relational skills, as well as reduced symptoms of depression. Some enthusiasts also report that microdosing LSD has helped them heighten their spiritual awareness and enhance their senses.
